The effects of Repatha were also studied in people who had high LDL and other cholesterol issues, some of whom were taking other cholesterol medicines. The studies lasted 12 to 80 weeks.

The U.S. Food and Drug Administration today approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL)cholesterol under control with current ...

Repatha’s website states that with self-purchased or employer-based insurance, 82% of commerical prescriptions of Repatha cost $49 or less per month.

In the big 2015 clinical trial on Repatha, also published in NEJM, the drug reduced patients’ LDL cholesterol levels by 61 percent, from a median of 120 milligrams per deciliter to 48 milligrams ...

Repatha is approved in more than 40 countries, including the U.S., Japan, Canada and in all 28 countries that are members of the European Union. Applications in other countries are pending.

If you do become pregnant while receiving Repatha, the drug manufacturer (Amgen) encourages you and your doctor to notify their pregnancy safety study. This study is a collection of data from ...

Amgen's Repatha was shown to reduce the risk of cardiovascular events, such as cardiovascular death and myocardial infarction, in phase 3 of the FOURIER study. Full results will be presented in ...

Amgen Inc's experimental drug Repatha lowered cholesterol in clinical trials and did not cause a marked disparity in deaths or serious adverse events but showed potential safety issues that should ...

Entree Health executives said that the agency is working on the payer-access strategy for Amgen’s Repatha. MM&M‘s coverage of the emerging PCSK9 market, so far: FDA approves first PCSK9 inhibitor ...

In general medicine, Repatha is Amgen’s key drug, which is now a multi-billion-dollar product. Repatha generated revenues of $696.0 million, up 31% year over year, driven by higher volume growth.

The pharmaceutical company Amgen announced Wednesday that it will lower the price of their cholesterol lowering drug Repatha by 60%. The company said some patients weren’t filling their ...